Current treatment for chronic hepatitis C virus (HCV) infection results 40-45% sustained virological response (SVR) rates in patients with HCV genotype 1, which is the most prevalent genotype in Europe and in Hungary. This therapy requires long duration, high costs and is associated with side effects. For these reasons, progress needs to develop more effective treatment regimes. In the past 5 years, advances have been made in better knowledge of HCV viral life cycle, and in the researches of HCV-specific directly acting antivirals. Recent data suggest that protease and polymerase inhibitors, in triple combinations with interferon plus ribavirin-based treatment are able to shorten treatment duration and improve SVR rates even in "hard to cure" HCV genotype 1 patients. The aim of this review is to summarize results obtained with novel anti-HCV compounds.
ASJC Scopus subject areas